comparemela.com

Latest Breaking News On - Hedge funds weigh in on fusion pharmaceuticals - Page 1 : comparemela.com

Fusion Pharmaceuticals Inc (NASDAQ:FUSN) Sees Significant Decline in Short Interest

Fusion Pharmaceuticals Inc. (NASDAQ:FUSN – Get Free Report) saw a significant drop in short interest in the month of April. As of April 15th, there was short interest totalling 4,860,000 shares, a drop of 6.5% from the March 31st total of 5,200,000 shares. Based on an average daily volume of 2,140,000 shares, the short-interest ratio […]

Q1 2024 Earnings Forecast for Fusion Pharmaceuticals Inc (NASDAQ:FUSN) Issued By William Blair

Fusion Pharmaceuticals Inc. (NASDAQ:FUSN – Free Report) – Equities research analysts at William Blair lifted their Q1 2024 EPS estimates for shares of Fusion Pharmaceuticals in a research report issued to clients and investors on Thursday, March 21st. William Blair analyst A. Hsieh now forecasts that the company will post earnings per share of ($0.39) […]

Q1 2024 Earnings Forecast for Fusion Pharmaceuticals Inc (NASDAQ:FUSN) Issued By Wedbush

Fusion Pharmaceuticals Inc. (NASDAQ:FUSN – Free Report) – Investment analysts at Wedbush decreased their Q1 2024 EPS estimates for Fusion Pharmaceuticals in a research note issued to investors on Wednesday, March 20th. Wedbush analyst D. Nierengarten now forecasts that the company will earn ($0.34) per share for the quarter, down from their prior estimate of […]

Fusion Pharmaceuticals (NASDAQ:FUSN) Receives Hold Rating from Jonestrading

Jonestrading reaffirmed their hold rating on shares of Fusion Pharmaceuticals (NASDAQ:FUSN – Free Report) in a research note issued to investors on Wednesday morning, Benzinga reports. Several other research firms also recently weighed in on FUSN. Royal Bank of Canada reiterated a sector perform rating and issued a $21.00 target price (up previously from $16.00) […]

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.